Welcome to our dedicated page for CERENOME SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERENOME's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERENOME's regulatory disclosures and financial reporting.
Cerenome, Inc. reported for the quarter and six months ended June 30, 2026 that it remains a development-stage CNS oncology company with no product sales and relies primarily on grant funding and capital markets. Grant revenue was $0.4 million for the quarter and $1.4 million year‑to‑date, down from 2025, while total operating expenses rose sharply to $9.5 million for the quarter and $17.6 million for the first half of 2026, producing a six‑month net loss of $15.9 million.
Total assets were $14.0 million, including $2.4 million in cash and cash equivalents and $6.2 million in investments, against total liabilities of $8.6 million. Net cash used in operating activities was $13.4 million in the first half, partially offset by $10.1 million of net cash provided by financing, including a January 2026 underwritten equity offering and at‑the‑market sales. Management states that recurring losses, high cash burn, and dependence on external financing raise substantial doubt about the Company’s ability to continue as a going concern. The company executed a 1‑for‑25 reverse stock split and is currently in compliance with Nasdaq stockholders’ equity and minimum bid price requirements, with monitoring continuing through August 22, 2026.
Cerenome, Inc., a CNS oncology company recently rebranded from Plus Therapeutics, reported financial results for the quarter ended June 30, 2026 and provided a business update. The company is advancing its integrated platform combining precision diagnostics, targeted radiotherapeutics and artificial intelligence.
Operationally, Cerenome continued enrollment in its REYOBIQ clinical programs for leptomeningeal metastases and glioblastoma and initiated site activation for the pediatric brain cancer trial, with first dosing expected in the third quarter of 2026. Its CNSide cerebrospinal fluid assay platform performed 232 tests in the first half of 2026 and achieved commercial payer coverage for 150 million covered lives, Medicare identifiers, CAP accreditation for its Houston laboratory, and several data and billing partnerships.
Financially, cash, cash equivalents and investments totaled $8.6 million as of June 30, 2026, unchanged from December 31, 2025. Second-quarter grant revenue was $0.4 million, down from $1.4 million a year earlier. Operating loss widened to $9.1 million from $1.5 million, and the company recorded a net loss of $9.0 million versus net income of $5.2 million in the prior-year quarter.
Cerenome, Inc., formerly Plus Therapeutics, Inc., implemented a corporate name change effective August 3, 2026. A Certificate of Amendment to its Amended and Restated Certificate of Incorporation was filed in Delaware on July 30, 2026 to effect this change.
In connection with the name change, the company’s common stock, par value $0.001 per share, began trading on the Nasdaq Capital Market under the new ticker symbol “CNSY” at the start of trading on August 3, 2026. The company states that there is no change to its CUSIP as a result of the name or trading symbol change, and it has updated its bylaws to reflect the new corporate name.
PLUS THERAPEUTICS director Ronald Asbury Andrews exercised equity awards, acquiring additional common stock through RSU vesting. On July 1, 2026, 922 Restricted Stock Units converted into 922 shares of common stock at a stated price of $0.00 per share as part of his compensation. Following the transaction, he directly holds 922 shares of common stock and 2,764 Restricted Stock Units that represent rights to receive the same number of shares, vesting in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS, INC. director Kyle Guse exercised restricted stock units to acquire 922 shares of Common Stock at no cost. After the transaction, he directly holds 922 Common shares. A related RSU grant totaling 2,764 units remains outstanding and vests in four substantially equal quarterly installments beginning on July 1, 2026.
PLUS THERAPEUTICS director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs), which were converted into an equal number of shares of Common Stock at a price of $0.00 per share. Following this transaction, the reporting person directly holds 922 shares of Common Stock.
The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, meaning this filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale, with no shares disposed of in the transaction.
PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick reported routine equity compensation activity as Restricted Stock Units vested into Common Stock. On July 1, 2026, RSU vesting resulted in the acquisition of 16,439 shares of Common Stock at an exercise price of $0.00 per share. Following these conversions, he directly holds 34,431 shares of Common Stock and 163,650 RSUs, which represent contingent rights to receive an equal number of shares. The RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026.
Plus Therapeutics director Howard Clowes exercised restricted stock units into common shares as part of equity compensation. On this Form 4, he acquired 922 shares of Plus Therapeutics common stock through the conversion of restricted stock units at a stated price of $0.00 per share.
Following the transaction, Clowes directly holds 1,981 shares of common stock and 2,764 restricted stock units. Each RSU represents a contingent right to receive one common share, with vesting in four substantially equal quarterly installments beginning on July 1, 2026. This filing reflects routine equity incentive vesting rather than an open-market stock purchase or sale.
PLUS THERAPEUTICS director Richard J. Hawkins reported a compensation-related equity transaction involving 922 shares. On July 1, 2026, 922 Restricted Stock Units (RSUs) vested, each RSU converting into one share of PLUS THERAPEUTICS common stock at a price of $0.00 per share.
The filing shows Hawkins directly holding 1,529 shares of common stock after the transaction, along with 2,764 RSUs that remain outstanding. According to the footnotes, this RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, highlighting that this is a scheduled equity award rather than an open‑market trade.
PLUS THERAPEUTICS, INC. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported equity compensation-related transactions in the company’s common stock. On July 1, 2026, he exercised or converted derivative awards into a total of 2,985 shares of common stock at a stated price of $0.0000 per share, reflecting non-cash vesting of awards.
The filing shows his direct holdings of common stock at 9,941 shares after one of the transactions, with 28,522 restricted stock units (RSUs) remaining after another. Footnotes state that each RSU represents a right to one common share and that the RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026, respectively. These transactions appear to be part of scheduled RSU vesting rather than open-market buying or selling.